Clinical Trial

Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.

Name: Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma. — clinical trial record (NCT06492408)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This trial is designed to investigate the safety, response rates and survival outcomes of patients with hepatocellular carcinoma by delivery of CTLA4 and PD1 or PDL1 antibodies combination through CT-guided intra-tumor (IT) injection.

Trial Details

NCT Number	NCT06492408
Lead Sponsor	Second Affiliated Hospital of Guangzhou Medical University
Conditions	Hepatic Cancer, Surgery
Enrollment	90 participants
Start Date	2024-07-01
Primary Completion	2028-12-30 (estimated)
Study Completion	2033-12-30 (estimated)
Updated on ClinicalTrials.gov	2024-07-09